Precigen is trading 4.05% up at $6.93, amid biotech-sector strength.
- No new company-specific announcement or catalyst for October 20 was identified; the latest listed company release predates this move.
- The provided sector data has XBI up 2.10%, amid sector-wide M&A activity and positive clinical-trial news.
- Merck’s planned acquisition of Silence Therapeutics is one reported example of broader activity, not a Precigen-specific catalyst.